Earnings Update
GSK India Reports Continued Profit Growth in FY26; Board Recommends ₹57 Final Dividend
NSE
glaxo
BSE
500660
GlaxoSmithKline Pharmaceuticals Limited (GSK India) reported stable FY26 growth driven by oncology, vaccines, pricing measures, and operational efficiencies. The company posted improved profitability and margin expansion despite supply-chain related challenges impacting topline growth during the year.
PRICE-SENSITIVE TRIGGER
Event: Q4 & FY26 Financial Results Announcement
Type: Earnings Update
Impact: Positive
Immediate Effect: Improved profitability, margin expansion, and a strong oncology pipeline reinforced investor confidence, while the board recommended a final dividend of ₹57 per share.
Key Metrics:
- FY26 Revenue: ₹3,790 Crore (+2% YoY)
- FY26 PAT: ₹1,012 Crore (+10% YoY)
- FY26 EBITDA Margin: 34% (+290 bps)
- Q4 FY26 Revenue: ₹989 Crore
- Q4 FY26 PAT: ₹275 Crore
- Q4 FY26 EBITDA Margin: 35% (+90 bps)
- Final Dividend Recommended: ₹57 per equity share
- Topline Growth: Impacted by supply-chain disruptions during FY26
Highlight:
- Label: Profit Growth
- Value: FY26 PAT increased 10% to ₹1,012 Crore
What Happened ?
GSK India announced its Q4 and FY26 financial results, reporting continued profitable growth supported by strong performance in oncology, vaccines, and operational efficiency initiatives.
The company highlighted that focused investments in innovative therapies, AI-led optimization, improved field force productivity, and disciplined cost management contributed to margin expansion during the year.
Management also stated that supply chain disruptions affected availability of certain products and constrained topline growth, though efforts are underway to strengthen sourcing resilience and inventory visibility.
key highlights
Business Performance & Portfolio Highlights:
- Oncology portfolio delivered strong growth led by therapies such as Jemperli and Zejula.
- Vaccines business maintained leadership in the self-pay private pediatric vaccines market.
- Shingrix continued gaining traction through increased preventive healthcare awareness.
- General Medicines portfolio outperformed the market in key promoted brands.
- Brands such as Augmentin, Calpol, and T-Bact maintained leadership positions.
- Supply chain disruptions impacted availability of select products during FY26.
- EBITDA margins expanded due to pricing measures and disciplined cost control.
- GSK India received market authorization for Blenrep (belantamab mafodotin) in India for relapsed or refractory multiple myeloma treatment.
- Management plans to continue investments in innovative and high-growth therapy areas.
Note:
- The company emphasized that Oncology is becoming a major growth driver as GSK India transitions toward an innovation-led pharmaceutical business model.
Risk Analysis
Key Risks
- Supply chain disruptions may continue affecting product availability.
- Dependence on specialty and oncology therapies increases execution sensitivity.
- Regulatory approvals and launch timelines for innovative therapies remain critical.
- Competitive pressure in core pharmaceutical segments could affect market share.
- Currency fluctuations and imported product dependencies may impact margins.
Worst Case Scenario
- If supply disruptions persist or innovative product launches underperform expectations, topline growth could remain constrained despite margin improvements.
Risk Level: Medium
Company Commentary
- Management stated Oncology represents a key inflection point in GSK India’s growth journey.
- The company plans to continue investing in innovative and high-growth therapy areas.
- GSK India highlighted focus on sustainable profitability and topline growth.
- The company reaffirmed its commitment to scientific rigor and patient-centric healthcare solutions.
- Management stated supply chain challenges accelerated efforts to strengthen sourcing resilience and contingency planning.
Official Exchange Filing: GSK India Limited